New data presented Sunday at the American Society for Radiation Oncology (ASTRO) Annual Meeting shows that precision medicine navigators (PMNs) increased the rate of genetic testing in Black prostate cancer patients six-fold. The findings have the potential to significantly reduce the health inequities and improve health outcomes for black patients.…

Black men with more aggressive disease appeared to have better outcomes than their white counterparts in a meta-analysis of radiation therapy trials, according to a study by UCLA Jonsson Comprehensive Cancer Center researchers. “These results provide high-level evidence challenging the common belief that Black men who are diagnosed with prostate…

The question of whose DNA or RNA was used to develop a complex genetic test, such as those that use AI to identify patterns of genetic variants or gene expression levels, is fundamental to its applicability—the people most like those who were used to develop the test are the most…

While it is well documented that Black men in the United States are more likely to develop prostate cancer than White men and have more advanced disease at diagnosis than their White counterparts, limited data is available to help guide prostate-specific antigen (PSA) testing for this at-risk population. Now, new…

City of Hope researchers have identified four metabolism-related biomarkers that may be associated with an increased risk for metastatic prostate cancer in men of West African heritage and could one day be incorporated into a disease prediction tool for this high-risk population. “We hope that our findings can become part…

The largest-ever study of prostate cancer genetics in black men has uncovered nine previously undiscovered variants that raise risk in this population. Seven of these variants are found either largely or exclusively in men of African descent. The study was led by Christopher Haiman, ScD, director of the Center for…

Black men suffer higher rates of prostate cancer, and now research points to genetic variants that may be responsible for early-onset prostate cancer among this population. Researchers at the Wayne State University School of Medicine and the Barbara Ann Karmanos Cancer Institute have found putative markers of the disease in…

Research carried out at Wayne State and Duke University Schools of Medicine has identified 26 unique genetic variants in Black men that appear to be associated with more severe prostate cancer in this population group. Prostate cancer is the most common cancer diagnosed in adult men in the U.S. Although…

Black men with prostate cancer may respond well to androgen deprivation therapy (ADT)-based regimens, but they are less likely to receive such therapy than non-Blacks, according to a new multi-institutional retrospective analysis. The study also found that black men with metastatic hormone-sensitive prostate cancer (mHSPC) are more likely to carry…

Research led by the University of California, Irvine shows RNA expression differences between prostate tumor and nearby tissue samples that could help explain why Black Americans are more severely affected by this type of cancer than White Americans. Black Americans are diagnosed with prostate cancer earlier and at a more…

Earlier this year, Princess Kate Middleton announced that she had cancer. The world responded with shock, partly because she’s only 42. Her 75-year-old father-in-law, King Charles, was also diagnosed almost simultaneously. His announcement drew widespread sympathy as well, but nothing like the shock that greeted Kate’s news. “She is so…

Huntsman Cancer Institute researchers have shown that less than a third of patients with metastatic prostate cancer or advanced urothelial carcinoma undergo next-generation sequencing (NGS), even though these tumors may have mutations that could be used to guide treatment. The NGS rates have increased over time, but were lower among…

In a first-of-its-kind study, researchers at University College London (UCL) have conducted a clinical trial to use MRI scans with PSA (prostate specific antigen) to aid in prostate cancer screening and assess the need for additional testing. The research, published in BMJ Oncology, showed that of the 29 participants in…

Medical genetics company Invitae announced that data from its PROCLAIM clinical trial shows the benefit of pathogenic germline variant (PGV) testing for all prostate cancer patients. According to the data, nearly half of all prostate cancer patients with clinically actionable inherited PGVs could be missing out on vital, targeted care…

A large-scale, longitudinal, study found that less than seven percent of cancer patients received germline genetic testing, even though it is recommended by practice guidelines to support targeted treatment and inform health decisions by relatives. The authors, who included researchers from Stanford and University of Michigan, noted that genetic testing…